Blood News and Research

RSS

UC receives grant to better understand how "microparticles" in blood contribute to inflammation, injury

A University of Cincinnati (UC) trauma and critical care researcher has received a National Institutes of Health grant to better understand how "microparticles" in stored blood can contribute to inflammation and injury after resuscitation from traumatic injury.

25 Mar 2014

Not all doctors offer cancer gene testing to patients, study finds

Many cancer researchers believe that cutting-edge advances in genomics will pave the way for personalized or "precision" cancer medicine for all patients in the near future. A new study by researchers at Dana-Farber Cancer Institute, however, suggest that not all doctors are ready to embrace tests that look for hundreds of DNA changes in patients' tumor samples, while others plan to offer this type of cancer gene testing to most of their patients.

25 Mar 2014

Diabetes drug reduces amyloid-beta peptides, improves memory in experimental AD models

Researchers from Boston University School of Medicine have found that the diabetic drug, pramlintide, reduces amyloid-beta peptides, a major component of Alzheimer's disease (AD) in the brain and improves learning and memory in two experimental AD models.

25 Mar 2014

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.

25 Mar 2014

Nasal spray holds promise as potential alternative therapeutic approach for depression

A nasal spray that delivers a peptide to treat depression holds promise as a potential alternative therapeutic approach, research from the Centre for Addiction and Mental Health (CAMH) shows.

25 Mar 2014

Treatment with natalizumab in patients with MS appears linked with JC virus infection

Treatment with natalizumab in patients with multiple sclerosis (MS) appears linked with JC virus (JCV) infection, which can lead to a rare and often fatal demyelinating disease of the central nervous system called progressive multifocal leukoencephalopathy (PML) that destroys the myelin that protects nerve cells.

25 Mar 2014

‘Residual risk’ concern for treated Japanese hypertension patients

Physicians should be alert to other sources of cardiovascular risk in patients with hypertension, even if they are receiving optimal antihypertensive treatment, say Japanese researchers.

24 Mar 2014

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

Research findings may be beneficial for creation of purer HSC lines for clinical treatments

Hematopoietic stem cells are now routinely used to treat patients with cancers and other disorders of the blood and immune systems, but researchers knew little about the progenitor cells that give rise to them during embryonic development.

24 Mar 2014

Drugs fail to "wake up" dormant reservoirs of HIV inside immune system T cells

Scientists at Johns Hopkins report that compounds they hoped would "wake up" dormant reservoirs of HIV inside immune system T cells - a strategy designed to reverse latency and make the cells vulnerable to destruction - have failed to do so in laboratory tests of such white blood cells taken directly from patients infected with HIV.

24 Mar 2014

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

24 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

24 Mar 2014

Study: Role of alcohol in U.S. traffic deaths may be underreported on death certificates

It's no secret that drinking and driving can be a deadly mix. But the role of alcohol in U.S. traffic deaths may be substantially underreported on death certificates, according to a study in the March issue of the Journal of Studies on Alcohol and Drugs.

24 Mar 2014

People with rare inherited mutated gene have high chance of getting lung cancer

People who have an inherited mutation of a certain gene have a high chance of getting lung cancer — higher, even, than heavy smokers with or without the inherited mutation, according to new findings by cancer researchers at UT Southwestern Medical Center. Although both genders have an equal risk of inheriting the mutation, those who develop lung cancer are mostly women and have never smoked, the researchers found.

24 Mar 2014

Measuring circulating tumor cells may help better predict prostate cancer survival

New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) - the cells that spread cancer through the body - may be a better predictor of patient survival than the prostate specific antigen (PSA).

24 Mar 2014

Scientists develop unique cells to repair patient's defective and diseased bladder

For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

24 Mar 2014

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

24 Mar 2014

Rare abnormality in chromosomes increases risk of rare childhood leukaemia

Researchers have found that people born with a rare abnormality of their chromosomes have a 2,700-fold increased risk of a rare childhood leukaemia. In this abnormality, two specific chromosomes are fused together but become prone to catastrophic shattering.

24 Mar 2014

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B.

21 Mar 2014

Blood News and Research

UC receives grant to better understand how "microparticles" in blood contribute to inflammation, injury

Not all doctors offer cancer gene testing to patients, study finds

Diabetes drug reduces amyloid-beta peptides, improves memory in experimental AD models

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Nasal spray holds promise as potential alternative therapeutic approach for depression

Treatment with natalizumab in patients with MS appears linked with JC virus infection

‘Residual risk’ concern for treated Japanese hypertension patients

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Research findings may be beneficial for creation of purer HSC lines for clinical treatments

Drugs fail to "wake up" dormant reservoirs of HIV inside immune system T cells

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

FDA approves Xolair for treatment of chronic idiopathic urticaria

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Study: Role of alcohol in U.S. traffic deaths may be underreported on death certificates

People with rare inherited mutated gene have high chance of getting lung cancer

Measuring circulating tumor cells may help better predict prostate cancer survival

Scientists develop unique cells to repair patient's defective and diseased bladder

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Rare abnormality in chromosomes increases risk of rare childhood leukaemia

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News